New Agents for AMD Preserve Vision, Dramatically Reduce Treatment Burden
MONTREAL — An investigational bispecific antibody for retinal disease achieved faster and numerically greater short-term improvements in visual acuity and retinal anatomy versus faricimab (Vabysmo), a randomized, proof-of-concept trial showed.…
